UniQure Shares Soar as Company to Seek US Approval for Huntington's Therapy Without New Study

UniQure NV's shares experienced a significant rise following the company's announcement regarding its Huntington’s disease gene therapy. The company stated it can now pursue US regulatory approval for the therapy without first conducting an additional study. This development marks a notable change in the typical drug review process.

By Fainaron·Jun 17, 2026 (3 days ago)·2 views

UniQure Shares Soar as Company to Seek US Approval for Huntington's Therapy Without New Study

UniQure NV shares saw a considerable increase after the company revealed it would be able to apply for US approval for its gene therapy designed to treat Huntington’s disease.

The crucial aspect of the announcement is that UniQure can now seek this approval prior to undertaking a new study. This decision has been characterized as a dramatic reversal in regulatory policy, suggesting a potential shift in the Trump administration's previous hard-line stance on drug reviews.

(Source: Bloomberg Markets)

#uniqure #huntington's disease #gene therapy #fda #drug approval #pharmaceuticals #stock market

Source attribution: This article was AI-curated and rewritten by Fainaron from a piece originally published by Bloomberg Markets. Read the original at Bloomberg Markets →

More like this

Two Men Arrested in Delaware for Waste Product Theft at Beachside Restaurants

Business

2 days ago

Two Men Arrested in Delaware for Waste Product Theft at Beachside Restaurants

Two individuals have been arrested in Delaware on charges related to the theft of a common waste product. The reported incidents occurred at beachside restaurants. Authorities believe this is not an isolated occurrence, suggesting a potential pattern of similar thefts.

Inc.com Magazine

Enterprises Face AI Credibility Gap Despite Widespread Claims

Business

2 days ago

Enterprises Face AI Credibility Gap Despite Widespread Claims

Organizations are increasingly making ambitious claims about their adoption of Artificial Intelligence (AI), yet measurable results often fall short, indicating a significant credibility gap. Studies show that billions in enterprise GenAI pilots have yielded nothing measurable, with over 40% of agentic AI projects predicted to be canceled by late 2027. Employee adoption also remains low, suggesting that while leaders tout AI as a transformative shift, practical, context-aware applications are crucial for gaining trust and demonstrating real value.

Fast Company

US Homeowners Adapt to Housing Market, Willing to Accept Higher Mortgage Rates

Business

2 days ago

US Homeowners Adapt to Housing Market, Willing to Accept Higher Mortgage Rates

A recent survey indicates a growing segment of U.S. homeowners are adapting to higher borrowing costs, with 47% stating they would accept a mortgage rate of up to 6% for their next home purchase. This sentiment marks a shift from earlier periods, suggesting a slow adjustment to elevated rates. Concurrently, homeowners anticipate a softer housing market with cautious expectations for home price changes over the next year.

Fast Company

Lululemon Faces Backlash in China Over Cultural Misstep at Great Wall Event

Business

2 days ago

Lululemon Faces Backlash in China Over Cultural Misstep at Great Wall Event

Activewear brand Lululemon encountered significant social media backlash in China after mistakenly using a Japanese taiko drum instead of a Chinese drum during a yoga festival on the Great Wall on Friday, May 30. The event, intended to celebrate Chinese culture and wellness with 2,000 guests, drew criticism when an image posted by Chinese actor Zhu Yilong highlighted the cultural error. Lululemon issued an apology on Tuesday via its Weibo account, removing related promotional materials, as discussions surrounding the incident reportedly reached 50 million viewers. The event marks another instance of a Western brand facing challenges with cultural sensitivity in the Chinese market.

Fast Company

Back to Homepage

UniQure Shares Soar as Company to Seek US Approval for Huntington's Therapy Without New Study

More like this

Two Men Arrested in Delaware for Waste Product Theft at Beachside Restaurants

Enterprises Face AI Credibility Gap Despite Widespread Claims

US Homeowners Adapt to Housing Market, Willing to Accept Higher Mortgage Rates

Lululemon Faces Backlash in China Over Cultural Misstep at Great Wall Event

Fainaron — live counters